Fig. 4From: Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging studyA Coronal view of cardiac uptake of [89Zr]Zr-dezamizumab and B whole-body standardised uptake values (immuno-PET study; all-treated population)Back to article page